The following is a summary of the Protalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Protalix reported Q4 revenues of $40.4 million, a significant increase of 60% compared to $25.3 million last year.

• Revenue from license and R&D services increased by 13% to $25.1 million, primarily attributed to regulatory milestone payments.

• Cost of goods sold showed an uptick of 17% to $23 million due to increased sales volumes.

• R&D expenses amounted to $17.1 million, marking a decrease of 42% from the previous year.

• Selling, general and administrative expenses escalated by 28% to $15 million.

• For the full year, the company posted a net income of $8.3 million, compared to a net loss of $14.9 million in the prior year.

Business Progress:

• Protalix was granted regulatory approval for its second drug, Elfabrio, in several countries in 2023, paving the way for increased sales.

• The company has made significant strides in the development of pipeline for innovative solutions aimed at treating both genetic and non-genetic rare diseases.

• Two significant pipeline candidates, PRX-115 (for severe gout treatment) and PRX-119 (for diseases associated with neutrophil extracellular scraps), are progressing well in their respective stages.

• The company saw a significant increase in sales of Elfabrio following its FDA and EMA approval, with expectations of a growing market share via sales to Chiesi.

• Dr. Eliott Foster was welcomed on board as Chairman of the Board of Directors in 2023.

More details: Protalix Biotherapeutics IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.